Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Urogenital Neoplasms 1Neoplasm Metastasis 1Melanoma 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1

Interventions

Sunitinib 2Paclitaxel 2valrubicin 1temsirolimus 1sipuleucel-T 1luprolide acetate gel depot 1ferumoxtran-10 1abiraterone 1abemaciclib 1Suspensions 1Surveys and Questionnaires 1Standard of Care 1Radiotherapy 1Prednisone 1Prednisolone 1Powders 1Pemetrexed 1Neoadjuvant Therapy 1National Cancer Institute (U.S.) 1Mitomycin 1Magnetic Resonance Spectroscopy 1Leuprolide 1Fatty Acids, Omega-3 1Educational Status 1Docetaxel 1Bevacizumab 1Atorvastatin 1Administration, Intravesical 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urogenital Neoplasms × National Cancer Institute (U.S.) × Clear all
NCT03480152 2020-06-02

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
5 enrolled 11 charts
DermatologicGastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡